ATE515258T1 - Mukosales verabreichungssytem - Google Patents

Mukosales verabreichungssytem

Info

Publication number
ATE515258T1
ATE515258T1 AT00901497T AT00901497T ATE515258T1 AT E515258 T1 ATE515258 T1 AT E515258T1 AT 00901497 T AT00901497 T AT 00901497T AT 00901497 T AT00901497 T AT 00901497T AT E515258 T1 ATE515258 T1 AT E515258T1
Authority
AT
Austria
Prior art keywords
compositions
vaccines
formulations
methods
well
Prior art date
Application number
AT00901497T
Other languages
English (en)
Inventor
Hans Ipsen
Rahbek Janne Uldal
Original Assignee
Alk Abello As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alk Abello As filed Critical Alk Abello As
Application granted granted Critical
Publication of ATE515258T1 publication Critical patent/ATE515258T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Vending Machines For Individual Products (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT00901497T 1999-02-05 2000-02-04 Mukosales verabreichungssytem ATE515258T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11889699P 1999-02-05 1999-02-05
DKPA199900155 1999-02-05
PCT/DK2000/000049 WO2000045847A1 (en) 1999-02-05 2000-02-04 Novel mucosal delivery system

Publications (1)

Publication Number Publication Date
ATE515258T1 true ATE515258T1 (de) 2011-07-15

Family

ID=26063341

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00901497T ATE515258T1 (de) 1999-02-05 2000-02-04 Mukosales verabreichungssytem

Country Status (10)

Country Link
EP (1) EP1146906B1 (de)
JP (1) JP2003517452A (de)
CN (1) CN1338947B (de)
AT (1) ATE515258T1 (de)
AU (1) AU771552B2 (de)
CA (1) CA2361377C (de)
DK (1) DK1146906T3 (de)
ES (1) ES2368987T3 (de)
HK (1) HK1041219B (de)
WO (1) WO2000045847A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1054199B (en) * 2000-08-09 2009-11-13 爱尔开-阿贝优公司 Parenteral vaccine formulations and uses thereof
US20020051794A1 (en) 2000-08-09 2002-05-02 Alk-Abello A/S Novel parenteral vaccine formulations and uses thereof
CA2512735C (en) 2003-01-07 2016-03-08 Yeda Research And Development Co. Ltd. Eye-drop vaccine containing copolymer 1 for therapeutic immunization
US20060115499A1 (en) * 2004-09-27 2006-06-01 Alk-Abello A/S Liquid allergy vaccine formulation for oromucosal administration
CA2586283A1 (en) * 2004-11-10 2006-05-18 Jens Brimnes Method of preventive treatment of allergy by mucosal administration of an allergy vaccine
AU2006299310A1 (en) 2005-10-04 2007-04-12 Alk-Abello A/S Solid vaccine formulation
DK1814516T3 (da) * 2005-11-04 2013-03-25 Alk Abello As Anvendelse af en flydende allergivaccineformulering til oromucosal indgivelse
CA2628226A1 (en) * 2005-11-04 2007-05-10 Alk-Abello A/S Use of a liquid allergy vaccine formulation for oromucosal administration
WO2009142772A2 (en) 2008-05-23 2009-11-26 Mastcell Pharmaceuticals, Inc. Methods and treatment for allergies and inflammation associated with gastrointestinal diseases
CN102441162B (zh) * 2010-10-04 2018-07-24 免疫产品美国股份有限公司 结核病的治疗和预防
EP3556398A1 (de) * 2018-04-16 2019-10-23 Croda Denmark A/S Phytate zur verwendung als ein biomoleküleabgabe- oder -adsorptionssystem
CN113966228A (zh) * 2019-06-11 2022-01-21 葛兰素史密斯克莱生物公司 黏膜疫苗配制剂
CN111658611B (zh) * 2020-04-13 2021-06-01 四川大学 一种基于微乳的疫苗递送系统及其制备方法和应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3329564A (en) 1965-06-28 1967-07-04 Parke Davis & Co Antacid preparations and means of producing the same
DE2126957B2 (de) 1971-05-29 1977-07-07 Schettler, Hermann, Dr, East Lan sing, Mich (VStA) Verfahren zur herstellung von impfstoffen gegen gaensehepatitis
US4233288A (en) * 1979-03-12 1980-11-11 Cornell John A Gum emulsified liquid package for delivering and preserving liquid content in the mouth
JPS61238728A (ja) 1985-04-16 1986-10-24 Mitsui Norin Kk 茶葉抽出物と活性水酸化アルミニウムとの抗潰瘍性複合体
IL84167A (en) 1986-10-24 1991-04-15 Southern Res Inst Oral delivery of bioactive agents to and through the peyer's patch by use of microencapsulation
JPH02124832A (ja) * 1988-07-08 1990-05-14 Toray Ind Inc インターヘェロンβ組成物
US5443832A (en) * 1990-04-16 1995-08-22 Institut Swisse De Recherches Experimentales Sur Le Cancer Hydroxyapatite-antigen conjugates and methods for generating a poly-Ig immune response
JP3132863B2 (ja) * 1991-10-24 2001-02-05 富山化学工業株式会社 徐放性口腔用軟膏
US5360792A (en) 1991-12-20 1994-11-01 Greenwich Pharmaceuticals Incorporated Anti-proliferative and anti-inflammatory compounds: 5- or 6-deoxy hexose monosaccharides having a saturated nitrogen-containing heterocycle at the 5- or 6-position bound through the nitrogen atom
US5972336A (en) * 1992-11-03 1999-10-26 Oravax Merieux Co. Urease-based vaccine against helicobacter infection
AU6414994A (en) 1993-03-18 1994-10-11 Cytimmune Sciences, Inc. Composition and method for reducing toxicity of biologically-active factors
GB9316745D0 (en) 1993-08-12 1993-09-29 Medeva Holdings Bv Vaccine compositions
JP3414539B2 (ja) * 1994-05-11 2003-06-09 有限会社ドット 経鼻吸収用組成物
WO1996040074A2 (en) * 1995-06-07 1996-12-19 Alkermes Controlled Therapeutics, Inc. Device for releasing aggregation-stabilized, biologically active agent
ATE277182T1 (de) * 1996-07-26 2004-10-15 Wyeth Corp Das nuca protein von haemophilus influenzae und dessen kodierender gen
AU753688B2 (en) * 1997-03-10 2002-10-24 Ottawa Civic Loeb Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
DE69822542T2 (de) * 1997-04-23 2004-08-05 Pfizer Inc. Verkapslung einer Untereinheit des Bovinen Herpes Virus Typ-1 in wässrigen Lösungsmitteln als Impfstoff.
JPH11216357A (ja) * 1998-02-03 1999-08-10 Tsutsumi Techno Planning Kk 生理活性物質用の吸着担体
JPH11286438A (ja) * 1998-03-31 1999-10-19 Shiseido Co Ltd 徐放性製剤
JPH11302184A (ja) * 1998-04-21 1999-11-02 Taisho Pharmaceut Co Ltd 点鼻用組成物
JPH11322582A (ja) * 1998-05-06 1999-11-24 Dot:Kk 経鼻吸収用鼻粘膜付着・滞留型キャリヤ

Also Published As

Publication number Publication date
JP2003517452A (ja) 2003-05-27
CA2361377C (en) 2009-02-03
DK1146906T3 (da) 2011-10-24
HK1041219B (en) 2011-10-21
AU2279700A (en) 2000-08-25
CN1338947A (zh) 2002-03-06
HK1041219A1 (en) 2002-07-05
ES2368987T3 (es) 2011-11-24
WO2000045847A1 (en) 2000-08-10
EP1146906B1 (de) 2011-07-06
EP1146906A1 (de) 2001-10-24
CA2361377A1 (en) 2000-08-10
AU771552B2 (en) 2004-03-25
CN1338947B (zh) 2012-11-14
WO2000045847A8 (en) 2010-12-02

Similar Documents

Publication Publication Date Title
ATE515258T1 (de) Mukosales verabreichungssytem
CY1110727T1 (el) Παρασκευασματα θετικων κατα gram βακτηριων για τη θεραπεια ασθενειων που περιλαμβανουν μια ανοσολογικη δυσρυθμιση
CY1106602T1 (el) Παραγωγα αδαμαντανιου για τη θεραπεια φλεγμονωδων, ανοσολογικων και καρδιαγγειακων ασθενειων
ES2114616T5 (es) Acidos dicarboxilicos alifaticos insaturados.
NO981746D0 (no) Utlevering av biologisk aktive polypeptider
GEP20053602B (en) Aripiprazole for Oral Administration
EE200200507A (et) Muundatud vaktsiiniaviirus Ankara (MVA), sellega nakatatud peremeesrakk ning seda sisaldav farmatseutiline kompositsioon, MVA valmistamine ja raviotstarbeline kasutamine
WO2003055513A3 (en) Bacillus subtilis spores to stimulate the immune responses
MD1586G2 (ro) Inducere a unui răspuns citotoxic T-limfocitar
NZ331651A (en) BSW17 peptide immunogens for vaccination against and treatment of allergy
FR2677654B1 (fr) Composes a effet immunogene anti-cytokine, a effet immunogene anticytostatique ou a effet vaccinal anti-infection a hiv.
GB0109297D0 (en) Vaccine
IS2670B (is) Bóluefni og notkun þar á til meðhöndlunar á blandaðri hreyfitaugahrörnun
AU1813701A (en) Interleukin-1 muteins useful as vaccine adjuvants
MXPA02005563A (es) Formulacion estable de interferon en solucion acuosa, metodo de preparacion y usos de la misma.
ATE399022T1 (de) Zusammensetzung und verfahren zur verstärkung der immunantwort antigen-präsentierender zellen
UA35611C2 (uk) Композиція місцевого застосування для інгібування росту волос у ссавців, спосіб із її використанням та композиція місцевого застосування для доставки водорозчинного фармакологічного засобу до шкіри
ATE458496T1 (de) Hiv-vakzine und anwendungsverfahren
WO1997005899A3 (en) Novel vaccines and pharmaceutical compositions using membrane vesicles of microorganisms, and methods for preparing same
WO2000045849A3 (en) Use of cationic lipids to generate anti-tumor immunity
WO2002058535A3 (en) Use of combretastatin a4 and its prodrugs as an immune enhancing therapy
AU5643299A (en) Humic acid and its use in the treatment of various conditions
AU3808795A (en) Water-soluble derivatives of epipodophyllotoxin, process for their preparation, their use as medicinal product and their intended use in anticancer treatments
WO2002053149A3 (de) Arzneimittel enthaltend ein polyamin als wirksubstanz
MY130445A (en) Novel formulations of alpha-2, 4-disulfophenyl-n-tert-butylnitrone

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties